Dermatophytic Onychomycosis – United States of America (USA) Drug Forecast and Market Analysis to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Onychomycosis (tinea unguium) of the toenail is a fungal infection of the nail by dermatophytic, nondermatophytic, or yeast species. Infection can occur in the nail matrix, nail bed, or nail plate. While dermatophytic onychomycosis (DO) is not considered life-threatening, it can cause discomfort, pain, and physical and occupational limitations. Onychomycosis patients can be identified as having thick or brittle nails, along with discoloration (white and opaque) and inflammation of the skin underneath the nail.
GlobalData estimates that sales of drugs in the US DO market were approximately $208.8M in 2018, not taking into account over-the-counter (OTC) treatments for the disease. As one of the largest onychomycosis markets in the world, the US is expected to see the market grow to $676.5M by 2028, at a Compound Annual Growth Rate (CAGR) of 12.5% from 2018–2028. This growth will be mainly driven by the launche of several new topical therapies. However, GlobalData expects the patents of Jublia and Kerydin, the only branded marketed products, to expire over the forecast and thus face generic competition.
The DO pipeline consists entirely of topicals, accounting for the moderate growth of the market over the next ten years. The three pipeline agents are Moberg Pharma’s MOB-015, Blueberry therapeutics’ BB2603-om, and Hallux Inc.’s HTS-519
Key Questions Answered
What are the key drivers behind the increasing uptake of both oral and topical DO drugs, and which drug class is expected to see greater gains over the forecast period?
When will the key patents of Jublia and Kerydin expire, and how will it affect drug sales and the overall DO market in the US?
What are the struggles for pipeline drug development in the DO market? Why does GlobalData expect the pipeline drugs to have a substantial impact on the marketspace during the forecast period?

Scope

Overview of DO, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized DO therapeutics market revenue, cost of therapy per patient, and treatment usage patterns, with the forecast covering 2018 to 2028.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DO therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DO therapy.

Analysis of the current and future market competition in the US DO therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

GlobalData’s epidemiology team forecast an increasing prevalence of DO, representing one of the main drivers for market growth.

Pipeline topical agents need to demonstrate efficacy on par with oral treatments through novel mechanisms of action.

Highly efficacious, yet safe therapy remains the highest unmet need of DO treatment.

Opportunities are expected in patients who prefer topical treatments in order to avoid any side effects and prevent drug-drug interactions with other medications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the US therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the US DO therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Actavis
Allergan
Anacor
Aventis
Bausch Health
Blueberry Therapeutics
Hallux Inc.
Merck & Co.
Moberg Pharma
Novartis
Pfizer
Sandoz
Topica Pharmaceuticals

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Dermatophytic Onychomycosis: Executive Summary

2.1 Dermatophytic Onychomycosis Market to Experience Mild Growth from 2018–2028

2.2 Early and Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves

2.3 Persistent Unmet Needs Will Be Partially Addressed Over the Forecast Period

2.4 Topicals Dominate the Dermatophytic Onychomycosis Pipeline

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Dermatophytic Onychomycosis (2018–2020)

5.5.1 Total Prevalent Cases of Dermatophytic Onychomycosis

5.5.2 Diagnosed Prevalent Cases of Dermatophytic Onychomycosis

5.5.3 Sex-Specific Diagnosed Prevalent Cases of Dermatophytic Onychomycosis

5.5.4 Age-Specific Diagnosed Prevalent Cases of Dermatophytic Onychomycosis

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Diagnosis

6.1.2 Clinical Practice

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Greater Cure Rates and Long-Term Relapse Prevention

8.3 Cheaper, More Efficacious Topical Treatments with Shorter Treatment Periods

8.4 Safer Systemic Treatments

8.5 Updated Guidelines for the Treatment of Onychomycosis

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Bausch Health’s Portfolio Assessment

10.4 Sandoz’s Portfolio Assessment

10.5 Moberg Pharma’s Portfolio Assessment

10.6 Blueberry Therapeutics’ Portfolio Assessment

10.7 Hallux Inc.’s Portfolio Assessment

11 Market Outlook

11.1 US

11.1.1 Forecast

11.1.2 Key Events

11.1.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – Key Opinion Leaders and Payers Interviewed for This Report

12.4.1 Key Opinion Leaders

12.4.2 Payers

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: Dermatophytic Onychomycosis: Key Metrics in the US

Table 2: Risk Factors and Comorbidities for DO

Table 3: Treatment Guidelines for DO

Table 4: Approved Onychomycosis Drug Cure Rates in Toenails

Table 5: Disease Management Criteria in the US

Table 6: Leading Treatments for DO, 2018

Table 7: Comparison of Therapeutic Classes in Development for Dermatophytic Onychomycosis, 2018–2028

Table 8: Bausch Health’s DO Portfolio Assessment, 2019

Table 9: Sandoz’s DO Portfolio Assessment, 2019

Table 10: Moberg Pharma’s DO Portfolio Assessment, 2019

Table 11: Blueberry Therapeutics’ DO Portfolio Assessment, 2019

Table 12: Hallux Inc.’s DO Portfolio Assessment, 2019

Table 13: Key Events Impacting US Sales for DO, 2018–2028

Table 14: DO Market – Drivers and Barriers in the US, 2018–2028

Table 15: Key Historical and Projected Launch Dates for DO

Table 16: Key Historical and Projected Patent Expiry Dates for DO

Table 17: High-Prescribing Physicians (non-KOLs) Surveyed

Figures

Figure 1: Sales Forecast by Class for DO in the US in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in DO During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of DO During the Forecast Period

Figure 4: Etiology of Onychomycosis

Figure 5: US, Total Prevalent Cases of DO, Men and Women, All Ages, 2018–2028

Figure 6: US, Diagnosed Prevalent Cases of DO, Men and Women, All Ages, 2018–2028

Figure 7: US, Diagnosed Prevalent Cases of DO, by Sex, All Ages, 2018

Figure 8: US, Diagnosed Prevalent Cases of DO, by Age, Men and Women, 2018

Figure 9: Onychomycosis Diagnostic Algorithm

Figure 10: Unmet Needs and Opportunities in DO

Figure 11: Overview of the US Development Pipeline in DO

Figure 12: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for DO in the US During the Forecast Period

Figure 13: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of DO During the Forecast Period

Figure 14: Analysis of the Company Portfolio Gap in DO During the Forecast Period

Figure 15: Sales Forecast by Class for DO in the US in 2018 and 2028

Frequently asked questions

Dermatophytic Onychomycosis – United States of America (USA) Drug Forecast and Market Analysis to 2028 thematic reports
Currency USD
$6,995

Can be used by individual purchaser only

$20,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Dermatophytic Onychomycosis – United States of America (USA) Drug Forecast and Market Analysis to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Dermatophytic Onychomycosis – United States of America (USA) Drug Forecast and Market Analysis to 2028 in real time.

  • Access a live Dermatophytic Onychomycosis – United States of America (USA) Drug Forecast and Market Analysis to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.